Catridecacog

CHEMBL2108282 Phase 4 Aprobado Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A recombinant coagulation factor XIII A-subunit used to prevent bleeding in patients with congenital factor XIII A-subunit deficiency, a rare inherited bleeding disorder. Factor XIII plays a critical role in clot stabilization by crosslinking fibrin strands. Monthly prophylactic infusions can significantly reduce the risk of spontaneous and traumatic bleeding.

Mecanismo de acción

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A recombinant coagulation factor XIII A-subunit used to prevent bleeding in patients with congenital factor XIII A-subunit deficiency, a rare inherited bleeding disorder. Factor XIII plays a critical role in clot stabilization by crosslinking fibrin strands. Monthly prophylactic infusions can significantly reduce the risk of spontaneous and traumatic bleeding.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Catridecacog is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108282. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.